Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.97), $0.13 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $8.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.